Objective: To examine the association between cerebral folate deficiency and autism, this study examined CSF 5-methyltetrahydrofolate (5-MTHF) concentrations in a group of young children with autism, investigated the natural variation in CSF 5-MTHF over time, and assessed the relationship between CSF 5-MTHF and symptoms.
not recruited based on neurologic symptoms of CFD. Our objectives were to characterize their CSF 5-MTHF levels, determine variability in CSF 5-MTHF over time, and evaluate the relationship between CSF 5-MTHF levels and symptoms of autism. As folate receptor autoantibodies have been reported to be present in a significant number of children with ASD, 19 anti-folate transport protein binding antibodies (immunoglobulin G [IgG] anti-FBP) were also assessed. METHODS Participants. Participants were drawn from a longitudinal study of 106 children with autism aged 2-6 years at baseline; 67 of these participants underwent at least one lumbar puncture (LP) during the study period of 2006-2013 and were included in the current report. A subset of these children (n 5 31) had a second LP. Eligible participants met DSM-IV-TR criteria for autistic disorder on the basis of the Autism Diagnosis Interview-Revised (or a Toddler version) 20 and the Autism Diagnostic Observation Schedule (ADOS). 21 Exclusion criteria included neurologic conditions such as cerebral palsy or aggressive or maladaptive behaviors that precluded participation in behavioral testing. Demographic data are shown in table 1.
Standard protocol approvals, registrations, and patient consents. All procedures were approved by an NIH Institutional Review Board. Written informed consent was obtained from the guardians of each participant. This study is registered with ClinicalTrials.gov (NCT00298246).
Clinical assessment. Information about birthweight, gestational age, neonatal care, history of epilepsy, use of medications, and use of special diets or dietary supplements was obtained from medical records and parents/guardians. Adaptive behavior was assessed with the Vineland Adaptive Behavior Scale, Second Edition. 22 Cognitive functioning was assessed with either Mullen Scales of Early Learning 23 or the Differential Ability Scales, Second Edition. 24 Developmental quotient (ratio of age equivalents to chronological age) was calculated for nonverbal cognitive ability, due to the confounding effects of autism symptoms on the verbal subscale. Severity of autism symptoms was rated with the ADOS calibrated severity score, which indexes the child's score by age and verbal ability (1 5 no symptoms, 10 5 most severe). 25 Procedures. Participants adhered to their usual regimens in the days leading up to the testing, but all were required to fast for at least 6 hours prior to sedation for the LP (MRI and venipuncture were also performed). Blood samples were collected 1-2 hours prior to the LP, except in one child from whom the serum folate sample was collected 10 months after the LP. Per study protocol, LPs were performed between approximately 10 AM and 11 AM. The study protocol included an LP for a portion of participants in the autism group; however, 39 participants were not eligible due to predefined age criteria or parental refusal, resulting in 67 time 1 LPs. Thirty-one (46%) of the 67 participants had a repeat LP 1-3 years (mean 6 SD 29.6 6 8.3 months) after their initial evaluation; these participants were not selected by the investigators for any clinical indication. The remainder of the sample either declined (n 5 12) or were not eligible due to changes in study procedures (n 5 24). Time 1 and time 2 are used to refer to data from the first and second LPs, respectively.
CSF samples were processed within 20 minutes of collection by centrifuging for 10 minutes at 1,000 RPM at 4°C, and then flash frozen in 10 and 20 mL aliquots and stored at 280°C. Blood was collected in SST tubes and sent to the NIH Clinical Center laboratory where serum total folate was measured by the NIH Clinical Center laboratory using competitive immunoassay method. Analyses of CSF 5-MTHF and the neurotransmitter metabolites 5-hydroxyindolacetic acid (5-HIAA), homovanillic acid (HVA), and 3-hydroxymethyldopa were performed by Medical Neurogenetics (Atlanta, GA) (http://www.mnglab.com/). CSF 5-MTHF was measured using high-performance liquid chromatography with electrochemical and fluorescence detection, as previously described. 26 Medical Neurogenetics also performed analysis of autoantibodies binding to the human folate receptor in the serum (IgG anti-FBP) using an ELISA-based assay. Plasma and CSF amino acids were measured by Mayo Medical Labs (Rochester, MN) using quantitative analysis by liquid chromatography-tandem mass spectrometry. CSF analysis was performed with batched samples upon completion of sample ascertainment. Thus, results and referrals for potential intervention to participants with low CSF 5-MTHF occurred after the second sample collection.
Although typically developing controls were recruited for the broader natural history study, ethical constraints prevented LPs in these participants. Thus, comparison data for CSF 5-MTHF were obtained from Medical Neurogenetics, representing 540 samples Statistical analysis. The general linear model was the primary method of analysis in this study. Within-group change over time was assessed using repeated measures, using fixed effects for visit and age. Group differences were evaluated controlling for age. The x 2 test was used to determine the statistical significance of comparisons on categorical variables; Fisher exact test was reported where cell sizes were small. All statistical procedures were carried out using SAS version 9.3. 27 The a was set to 0.05.
RESULTS
In the 67 children with autism, CSF 5-MTHF at baseline ranged from 27.0 to 96.0 nmol/L (figure, . Mean time to follow-up was 29.7 6 8.3 months (range 14-43 months). A moderate correlation with a very wide confidence interval (CI) was observed between time 1 and time 2 CSF 5-MTHF measurements (n 5 31; Pearson r 5 0.38, p 5 0.04; 95% CI 0.02-0.64). CSF 5-MTHF decreased in 21 (68%) participants. Although the group average decrease was only 26% (time 1 mean 6 SD 58.5 6 13.5 nmol/L; time 2 mean 6 SD 52.5 6 15.5 nmol/L), significant variation of CSF 5-MTHF was observed within individual participants. Further, when age was controlled, this decrease was not statistically significant (F 5 0.16, p 5 0.69). It is noteworthy that 7 (23%) participants had CSF 5-MTHF values less than 40 nmol/L at time 2, though only one of these children had been classified as low at time 1. Of the 5 participants classified as low at time 1, 2 had follow-up (both received multivitamins but no folic acid supplementation), and only one remained low at time 2.
Time 1 samples were compared to those from an age-matched comparison group obtained from Medical Neurogenetics (n 5 140; mean 6 SD 3.9 6 1.3 years). In the comparison sample, values ranged from 20.5 to 151.2 nmol/L (mean 6 SD 77.5 6 26.2 nmol/L). Twelve (9%) participants had low 5-MTHF, with values ranging from 20.5 nmol/L to 39.1 nmol/L (mean 6 SD 30.5 6 6.6 nmol/L). Age was initially entered into the analysis of covariance model, but was excluded as it was nonsignificant. Mean CSF 5-MTHF values were significantly lower in the children with autism than in the reference group (F 1,205 5 25.67, p , 0.0001; Cohen d 5 0.8, 95% CI 0.5-1.1).
CSF folate receptor protein IgG anti-FBP. At time 1, 4 (6%) participants had elevated antibodies binding to the folate receptor protein (IgG anti-FBP) (66, 71, 84, and 153 pmol/mL). All of these participants Clinical correlates. We explored possible clinical correlates of 5-MTHF status using separate general linear models, controlling for age (table 3) . CSF 5-MTHF was not significantly associated with any measures of adaptive behavior, cognitive ability, or ASD symptom severity. Nor was change in CSF 5-MTHF level associated with change in any of the adaptive behavior, cognitive, or autism symptom measures. Overall, the clinical evaluation revealed few abnormalities for any of the children, including the 11 who had 5-MTHF ,40 nmol/L at either time point. Of 5 children with a seizure disorder, one had CSF 5-MTHF ,40 nmol/L at time 2 only (medications included oxcarbazepine, clonidine, and multivitamin). Physical and neurologic examinations conducted at time 1 (n 5 63) were unremarkable except for neurobehavioral abnormalities and hypotonia in 19 of 57 children, 2 of whom had CSF 5-MTHF ,40 nmol/L (data on hypotonia were missing for 6 children who received physical examinations). The percentage of children on special diets is indicated in table e-1 on the Neurology ® Web site at Neurology.org. At a given timepoint, participants with CSF 5-MTHF less than 40 nmol/L were likelier to consume a gluten-free or casein-free diet than the remainder of the sample (time 1, 60% vs 35%, nonsignificant; time 2, 86% vs 13%, p , 0.01). At both time 1 and time 2, no participant with low CSF 5-MTHF was taking valproic acid, which may cause folate depletion.
Genetic studies of children in the sample revealed 3 pathogenic abnormalities. Specifically, chromosomal microarray analysis found a pathogenic copy number variation in one child with 2p25.3 duplication and 9p24.3-p23 deletion translocation confirmed with FISH, clinically indicated targeting sequencing found one child with a pathogenic 15q14 mutation (i.e., Legius syndrome), and karyotyping had identified one child with Turner syndrome. Only the child with Turner syndrome had CSF 5-MTHF ,40 nmol/L, observed only at time 2.
DISCUSSION The primary finding of this study is that the clinical features of autism were not associated with absolute levels of CSF 5-MTHF or with the considerable variability in CSF 5-MTHF over time. CSF 5-MTHF less than 40 nmol/L was observed in 11 of 67 children in 1 of 2 LPs; of the 5 participants with low 5-MTHF at time 2, only one had been low at time 1. Importantly, low 5-MTHF levels were not associated with motor or other neurologic symptoms previously reported among patients with CFD. With the exception of diet, individuals with low 5-MTHF levels in our study group were indistinguishable from other children with ASD in both behavior and laboratory assays. Further, variability in CSF 5-MTHF concentrations occurred across timepoints, with low CSF 5-MTHF values found at time 1 but not time 2, or vice versa.
All studies that assess pediatric CSF are limited by the absence of reference values from healthy children as well as the lack of understanding of the natural variability over time of this metabolite. Our results emphasize that the natural variation on CSF 5-MTHF can be large, calling into question the value of single timepoint measurements. Since ethical restrictions preclude LPs from being performed for research studies among healthy, typically developing children, results for the children with autism were compared against a group of children with neurologic problems, including CFD. CSF 5-MTHF values ranged up to 151.2 nmol/L in this comparison group, while the maximum value observed in the autism group at time 1 was only 96.0 nmol/L. The lower bounds of the samples were similar, as were the rates of values less than 40 nmol/L (autism, 7%; comparison, 9%). It is worth noting that the comparison data were obtained between 1995 and 2000, so they were not collected or analyzed contemporaneously with the ASD data. The current ASD data are more similar in range to another recent study of ASD, 19 and to one in children without ASD (analyzed by a different Table 2 Laboratory results (n 5 67) Abbreviations: 5-MTHF 5 5-methyltetrahydrofolate; IQR 5 interquartile range. All serum folate samples were collected on the same day as each patient's CSF sample with the exception of one child whose serum folate sample was collected 10 months after CSF collection.
laboratory), 28 with the exception of values lower than 40 nmol/L. Given the constraints on LPs in healthy children, future studies may consider control groups comprised of children who receive LPs for specific medical problems such as headaches with no pleocytosis or idiopathic intracranial hypertension. Existing studies generally converge upon 40 nmol/L as the lower limit of normal CSF 5-MTHF. 2,3 Using the limit of 40 nmol/L, 11 children with autism (but without other neurologic abnormalities) were found to have low CSF 5-MTHF concentrations at either time 1 or time 2. The lack of stability across measurements and the failure to find correlation between behavioral measures and CSF 5-MTHF levels are evidence against the role of CSF 5-MTHF in the etiology of autism. In fact, CSF 5-MTHF decreased over time for a subgroup of children with autism, consistent with cross-sectional studies showing decreasing CSF 5-MTHF with age in healthy children. 28 This gives rise to the possibility that detection of a low CSF 5-MTHF at a single time point merely identifies natural biological variability, rather than a causal mechanism of autism. This may also be true of the other disorders that have sometimes been linked to CFD. Furthermore, only 4 participants had elevated levels of anti-folate binding receptor protein antibodies at either time point, and none had low CSF 5-MTHF. This suggests that autoantibodies were not a major contributor to low CSF 5-MTHF concentrations in this cohort and that the relationship between autism and autoantibodies may only be present in certain patient groups. 29 The results of this study do not permit determination of the cause for CSF 5-MTHF variability. 5-MTHF levels did not appear to impact ASD symptoms in this sample, nor were decreasing 5-MTHF concentrations associated with worsening symptoms.
This investigation represents the largest collection of CSF from an ASD cohort to date. It is also unique for having longitudinal samples and analyses. Low CSF 5-MTHF levels were found in only a small fraction of children with ASD, and were neither consistent across time nor associated with clinical symptoms or behavioral characteristics. Our data do not support the use of LP for assessment of CSF 5-MTHF in autism.
Our results demonstrate that all studies investigating CSF 5-MTHF must consider the natural variation of CSF 5-MTHF over time. The results of this study underscore the need for pediatric CSF normative data, which has been a persistent limitation in the study of CNS activity in children with neurologic disease.
AUTHOR CONTRIBUTIONS
John Shoffner: contributed to design of the study, interpretation of data, and revising the manuscript. Barbara Trommer: contributed to analysis and interpretation of the data and drafting the manuscript. Audrey Thurm: contributed to conceptualization and design of the study, analysis and interpretation of data, and drafting and revising the manuscript. Cristan Farmer: contributed to analysis and interpretation of data and drafting and revising the manuscript. William Langley: contributed to analysis of the data. Laura Soskey: contributed to analysis of the data. Aldeboran N. Rodriguez: contributed to analysis of the data. Precilla D'Souza: contributed to analysis of the data. Sarah Spence: contributed to the conceptualization of the study. Keith Hyland: contributed to design of the study, interpretation of data, and revising the manuscript. Susan Swedo: contributed to conceptualization and design of the study, interpretation of data, and revising the manuscript. Dr. Swedo is the Guarantor of this research. SD 5 15) . Seven children were out of age range for Vineland Adaptive Behavior Scale Motor Skills at time 2. "Predicting time 1 CSF 5-MTHF" section provides statistical relationships between time 1 CSF 5-MTHF and time 1 phenotypic scores, controlling for age. "Predicting change in CSF 5-MTHF" section provides statistical relationships between changes in both CSF 5-MTHF and phenotypic scores from time 1 to time 2, controlling for age and time to follow-up.
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